Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;48(5):761-766.
doi: 10.1007/s15010-020-01475-8. Epub 2020 Jul 13.

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

A T Coste #  1 , A Kritikos #  2 , J Li  1   2 , N Khanna  3 , D Goldenberger  4 , C Garzoni  5 , C Zehnder  6 , K Boggian  7 , D Neofytos  8 , A Riat  9 , D Bachmann  1 , D Sanglard  1 , F Lamoth  10   11 ; Fungal Infection Network of Switzerland (FUNGINOS)
Collaborators, Affiliations

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

A T Coste et al. Infection. 2020 Oct.

Abstract

Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.

PubMed Disclaimer

Conflict of interest statement

Author Zehnder C. was employed by company SYNLAB Suisse SA, Bioggio, Switzerland. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73:i4–i13. doi: 10.1093/jac/dkx444. - DOI - PMC - PubMed
    1. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18:19–37. doi: 10.1111/1469-0691.12039. - DOI - PubMed
    1. Shields RK, Nguyen MH, Press EG, Cumbie R, Driscoll E, Pasculle AW, et al. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection. Antimicrob Agents Chemother. 2015;59:7465–7470. doi: 10.1128/AAC.01973-15. - DOI - PMC - PubMed
    1. Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat. 2013;16:81–95. doi: 10.1016/j.drup.2014.01.001. - DOI - PubMed
    1. Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis. 2014;59:819–825. doi: 10.1093/cid/ciu407. - DOI - PubMed

LinkOut - more resources